Close Menu

NEW YORK – Driven by recent advances in genome technologies, expanded carrier screening, defined as testing for more than 20 hereditary disorders across ancestral groups, has become increasingly popular.

But laboratories offering such testing must be aware of still-controversial areas and potential pitfalls, according to Linda Hasadsri, co-director of the genomics laboratory and an assistant professor in the Department of Laboratory Medicine and Pathology at the Mayo Clinic.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.